Federal research is important, but companies turn it into actual treatments

JOHN MARAGANORE | April 11, 2019

article image
The March 27 front-page article “Pharma giant profits from HIV drug” perpetuated a misleading narrative in the drug pricing debate. The federal government plays a vital role as our society seeks to conquer disease and alleviate human suffering. Its support of basic research expands our scientific knowledge, which then serves as building blocks in the labs of biotech companies to develop innovative medicines. However, taking this basic research and developing it in into a safe, effective therapy for patients is a long and costly process. Twenty years ago, National Institutes of Health-funded research led to the discovery of RNA interference as a natural pathway to control gene expression in worms and then in other animal cells. NIH funding was less than $10 million. For 17 years, my company has worked to transform this research into treatments for rare diseases.

Spotlight

MoleMann Mental Health

MoleMann Mental Health is an innovative, small-scale mental healthcare organization. We treat adults and children with psychological and psychiatric problems. Our homely establishments are spread throughout the Netherlands. MoleMann also has a branch in Suriname. Characteristic of our method is that we always involve family and other relatives in the treatment and recovery of our patients. The patient's request for help is the starting point here. We carefully adjust the treatment offer to the wishes of our patients.

OTHER ARTICLES

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Spotlight

MoleMann Mental Health

MoleMann Mental Health is an innovative, small-scale mental healthcare organization. We treat adults and children with psychological and psychiatric problems. Our homely establishments are spread throughout the Netherlands. MoleMann also has a branch in Suriname. Characteristic of our method is that we always involve family and other relatives in the treatment and recovery of our patients. The patient's request for help is the starting point here. We carefully adjust the treatment offer to the wishes of our patients.

Events